Form 8-K NxStage Medical, Inc. For: Feb 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Selloff in NxStage Medical (NXTM) Seems 'Excessive'; BTIG Reaffirms at 'Buy'
February 11, 2016 9:48 AM ESTBTIG is out in defense of NxStage Medical, Inc. (NXTM) following the company's Q4, FY16 results reported on Wednesday. The firm rates NxStage at Buy with a price target of $27.
Analyst Sean Lavin noted that NxStage posted FY16 revenue of $336 million, which exceeded the company's outlook of $332 - $333 million. But, a... More
